In contrast, in early tumor shrinkage–negative patients on bevacizumab-based therapy showed a trend toward better overall survival, PFS, and postprogression survival outcomes compared with patients on anti-EGFR–based therapy (overall survival, HR = 1.22 [95% CI = 1.00 to 1.48]; PFS, HR = 1.27 [95% CI = 1.05 to 1.53]; postprogression survival, HR = 1.13 [95% CI = 0.90 to 1.43]). The gene discussed is EGFR; the disease is neoplasm.